Yes. Compounded tirzepatide is available in 2026, dispensed by state-licensed 503A pharmacies on patient-specific prescriptions. The FDA resolved the tirzepatide shortage on December 19, 2024, ending the 503B bulk compounding window. 503A patient-specific compounding continues under state pharmacy law.<\/p>\n
The supply chain narrowed in 2025 as bulk sellers exited or were sued by Eli Lilly. The 503A pharmacies that documented patient-specific clinical needs and used FDA-registered API suppliers kept operating through 2026. Prices stabilized at $249-$549 per month for adult maintenance dosing.<\/p>\n
This article covers the legal status, the FDA history, what changed after the lawsuits, and how to access compounded tirzepatide responsibly.<\/p>\n
At TrimRx, we believe that understanding your options is the first step toward a more manageable health journey. You can take the free assessment quiz if you’re ready to see whether a personalized program is a fit for you.<\/p>\n
The FDA placed tirzepatide on its Drug Shortage List in December 2022.<\/strong> During the shortage, 503B outsourcing facilities could compound copies under section 506E of the FD&C Act. The FDA removed tirzepatide from the shortage list on December 19, 2024.<\/p>\n Quick Answer: FDA resolved tirzepatide shortage December 19, 2024; 503B compounding exemption ended that date<\/p>\n After that date, 503B facilities can no longer mass-produce tirzepatide copies. 503A patient-specific compounding remains available when the pharmacy and prescriber follow state law and document a clinical reason the commercial product can’t meet.<\/p>\n Yes, under defined conditions.<\/strong> The pharmacy must be licensed in the patient’s state (or hold a non-resident license). The prescription must be patient-specific. The compounded formulation must differ in a clinically meaningful way from Mounjaro\u00ae or Zepbound\u00ae (different concentration, different excipients, addition of B12 or other components for clinical reasons, removal of an excipient the patient can’t tolerate).<\/p>\n Pharmacies that produce tirzepatide identical to brand without documented clinical justification risk enforcement action.<\/p>\n Eli Lilly filed multiple lawsuits in 2024-2025 against compounders selling tirzepatide outside 503A bounds.<\/strong> Some defendants settled, some closed operations, and some continue litigating. The outcome of the lawsuits accelerated market consolidation.<\/p>\n Bulk compounders that priced tirzepatide at $199-$249 monthly under the shortage exemption mostly exited or pivoted. Quality 503A operators with proper documentation, US-licensed prescribers, and FDA-registered API sourcing continued. Their prices reflect actual compliance costs.<\/p>\n Any licensed prescriber (MD, DO, NP, PA) with prescriptive authority in the patient’s state can prescribe.<\/strong> Telehealth platforms employing licensed providers can offer compounded tirzepatide in states where pharmacy and telehealth law permit it.<\/p>\n A few states have tighter rules on compounding for telehealth-only relationships. Most states accept properly documented telehealth prescriptions to 503A pharmacies.<\/p>\n Mounjaro (tirzepatide for diabetes) and Zepbound (tirzepatide for weight loss and OSA) are fully available through retail pharmacies in 2026.<\/strong> Insurance covers Mounjaro for diabetes broadly. Zepbound coverage for weight loss varies; LillyDirect offers vials at $349-$499 per month for self-pay patients.<\/p>\n Compounded tirzepatide remains lower-priced than Zepbound vials in most cases, but the gap narrowed in 2025-2026.<\/p>\n Most compounded tirzepatide ships as multi-dose vials, typically 10mg\/ml or 20mg\/ml concentration, with bacteriostatic water for reconstitution.<\/strong> Patients self-inject weekly with 29-31G insulin syringes.<\/p>\n Some compounders ship prefilled syringes for convenience. Pen-style auto-injectors are uncommon in compounded products because of manufacturing complexity.<\/p>\n SURMOUNT-1 (Jastreboff et al.<\/strong> 2022 NEJM) randomized 2,539 adults with obesity to placebo, 5mg, 10mg, or 15mg tirzepatide weekly. At 72 weeks, mean weight loss was 15.0% (5mg), 19.5% (10mg), and 20.9% (15mg) versus 3.1% placebo.<\/p>\n SURMOUNT-OSA (Malhotra et al. 2024 NEJM) led to FDA approval of Zepbound for obstructive sleep apnea in December 2024. SURPASS-2 (Frias et al. 2021 NEJM) showed 2.46% A1c reduction in type 2 diabetes.<\/p>\n That trial data applies to the tirzepatide molecule regardless of formulation, when dose is matched.<\/p>\n Key Takeaway: Lilly lawsuits in 2024-2025 forced bulk compounders to exit; quality 503A operators continue<\/p>\n Compounded tirzepatide with B12, with NAD+, or with Lipo-C is available from various pharmacies.<\/strong> None of those combinations are FDA-approved. Trial evidence for added efficacy beyond plain tirzepatide is limited or nonexistent.<\/p>\n For most adults, plain compounded tirzepatide is the right starting point. Combo formulations make sense with a documented clinical reason.<\/p>\n Yes. TrimRx partners with US-licensed 503A pharmacies and licensed prescribers. The free assessment quiz screens patients for medical eligibility, contraindications (personal or family history of medullary thyroid cancer, MEN 2 syndrome, prior pancreatitis), and patient-specific factors documenting clinical need.<\/p>\n The personalized treatment plan handles titration from 2.5mg through 15mg as tolerated. Pricing tracks the 503A market range.<\/p>\n Check three things. First, NABP Verified Pharmacy Program listing or state pharmacy board license search. Second, named pharmacist-in-charge and physical pharmacy address (not just a PO box). Third, willingness to share a recent batch certificate of analysis on request.<\/p>\n Red flags include prices sustained under $200 per month for adult maintenance doses, no licensed pharmacist named, products labeled “research only,” and overseas-style “peptide research chemical” framing.<\/p>\n A handful of states tightened compounding rules in 2024-2025.<\/strong> Most states allow telehealth-prescribed compounded tirzepatide from properly licensed pharmacies. A few require in-state prescriber relationships or specific documentation patterns.<\/p>\n State eligibility is checked at the assessment stage on responsible telehealth platforms.<\/p>\n The FDA monitors supply continuously.<\/strong> If a regional or national shortage recurred, 503B bulk compounding under the shortage exemption could resume. 503A patient-specific compounding doesn’t depend on shortage status and continues regardless.<\/p>\n Lilly has scaled manufacturing significantly through 2024-2025, so another sustained shortage is less likely but not impossible.<\/p>\n The mid-tier compounded price ($249-$549 monthly) is fairly stable.<\/strong> The bottom-tier price ($199 or below) is rare and usually a starter-month promotion, not sustained. Brand pricing through LillyDirect vials is creeping downward as Lilly competes for self-pay market share.<\/p>\n Realistic expectation through late 2026: brand vials around $350-$500 monthly, quality compounded $300-$450. The gap is real but smaller than 2023.<\/p>\n Bottom line: SURMOUNT-1 (Jastreboff et al. 2022 NEJM) showed 20.9% mean weight loss at 72 weeks on injectable tirzepatide 15mg<\/p>\n Yes, when prescribed by a licensed provider and dispensed by a state-licensed 503A pharmacy for a patient-specific clinical need. 503B shortage-based compounding ended December 2024.<\/p>\n $249-$549 per month from quality 503A operators is typical. Prices below $200 sustained should be questioned. Prices over $600 are above market.<\/p>\n Lilly argued some compounders were operating outside 503A patient-specific bounds, essentially making bulk copies of Mounjaro\/Zepbound under the shortage cover. After the FDA resolved the shortage in December 2024, the legal basis for bulk compounding ended.<\/p>\n Many patients do, usually for cost. A licensed provider matches the dose and continues titration. Don’t stop abruptly, GI side effects can return on restart.<\/p>\n The molecule is the same. SURMOUNT-1 data on injectable tirzepatide applies to the active drug. Real-world results vary by dose, adherence, and pharmacy quality.<\/p>\n 503A is patient-specific compounding by state-licensed pharmacies. 503B is bulk outsourcing under FDA cGMP, allowed without patient-specific scripts only during declared shortages.<\/p>\n Check the state pharmacy board license, look for NABP Verified Pharmacy listing, confirm a named pharmacist-in-charge and physical address, and request a recent certificate of analysis.<\/p>\n Disclaimer:<\/strong> This content is for informational purposes only and does not constitute medical advice. It is not intended to diagnose, treat, cure, or prevent any disease or condition. Individual results may vary. Always consult a qualified healthcare professional before starting any weight loss program or medication.<\/p>\n","protected":false},"excerpt":{"rendered":" Yes. Compounded tirzepatide is available in 2026, dispensed by state-licensed 503A pharmacies on patient-specific prescriptions.<\/p>\n","protected":false},"author":11,"featured_media":90106,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"inline_featured_image":false,"_yoast_wpseo_title":"Is Compounded Tirzepatide Available in 2026","_yoast_wpseo_metadesc":"Yes. Compounded tirzepatide is available in 2026, dispensed by state-licensed 503A pharmacies on patient-specific prescriptions.","_yoast_wpseo_focuskw":"compounded tirzepatide","footnotes":"","_flyrank_wpseo_metadesc":""},"categories":[9],"tags":[],"class_list":["post-90107","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-tirzepatide"],"_links":{"self":[{"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/posts\/90107","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/users\/11"}],"replies":[{"embeddable":true,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/comments?post=90107"}],"version-history":[{"count":1,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/posts\/90107\/revisions"}],"predecessor-version":[{"id":91605,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/posts\/90107\/revisions\/91605"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/media\/90106"}],"wp:attachment":[{"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/media?parent=90107"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/categories?post=90107"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/tags?post=90107"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}Is 503A Tirzepatide Compounding Still Legal?<\/h2>\n
What Did the Lilly Lawsuits Accomplish?<\/h2>\n
Who Can Prescribe Compounded Tirzepatide?<\/h2>\n
How Does This Compare to Mounjaro and Zepbound Availability?<\/h2>\n
What Dose Forms Are Available Compounded?<\/h2>\n
What’s the SURMOUNT Data Behind This?<\/h2>\n
What About Combo Formulations?<\/h2>\n
Is TrimRx Still Selling Compounded Tirzepatide?<\/h2>\n
How Do You Find a Quality Compounder?<\/h2>\n
What About State-level Restrictions?<\/h2>\n
What If Tirzepatide Returns to Shortage?<\/h2>\n
How Is Pricing Trending?<\/h2>\n
FAQ<\/h2>\n
Is Compounded Tirzepatide Legal in 2026?<\/h3>\n
How Much Does Compounded Tirzepatide Cost in 2026?<\/h3>\n
Why Did Lilly Sue Compounders?<\/h3>\n
Can I Switch From Zepbound to Compounded Tirzepatide?<\/h3>\n
Is Compounded Tirzepatide as Effective as Mounjaro?<\/h3>\n
What’s the Difference Between 503A and 503B Compounding?<\/h3>\n
How Do I Verify a Pharmacy Is Legitimate?<\/h3>\n